ERBB2 and breast cancer: We evaluated the effects of immunohistochemistry subtype, tumor size, and nodal spread on breast cancer mortality; however, our collected data did not include Ki67 status, and therefore, we could not analyze the combined effects of the aforementioned factors (i.e., hormone receptor status, HER2 status and Ki67 status) on breast cancer death.